Methods	Multicentre, randomised, double-blind, placebo-controlled, cross-over, not enriched. No imputation method mentioned Titration over 2 weeks from 300 mg to maximum pain reliefat a tolerable dose or 2400 mg daily, then stable dose for 3 weeks (5 weeks total); 3-week washout, then cross-over
Participants	Peripheral nerve injury with pain ≥ 6 months. N = 120, mean age 49 years, 53% women. PI at randomisation > 30/100, initial pain intensity 53/100 Efficacy analysis based on 98 who completed both treatment periods
Interventions	Gabapentin 2400 mg daily (max) Placebo Mean daily dose of gabapentin 2243 ± 402 mg Paracetamol ± codeine and dextropropoxyphene permitted as rescue medication Analgesics and NSAIDs used by ~50% during study
Outcomes	≥ 50% pain relief (weekly mean pain score) ≥ 30% pain relief Marked pain relief (5-point scale) Marked or moderate pain relief (5-point scale) Adverse events Withdrawals
Notes	Oxford Quality Score: R = 2, DB = 2, W = 1, Total = 5
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Yes	Central, remote allocation, “sealed code envelope”
Blinding? All outcomes	Yes	“capsules that were identical in appearance”
Incomplete outcome data addressed? Efficacy	Unclear	Imputation not mentioned
Size Efficacy	Unclear	120 randomised
Study duration Efficacy	Unclear	5-week period
Outcomes reported	Yes	At least 50% reduction in pain